tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Stephen Unger, 66 are a BUY (90.41%), 6 are a HOLD (8.22%), 1 are a SELL (1.37%).
Analyst Stephen Unger, carries an average stock price target met ratio of 87.36% that have a potential upside of 29.28% achieved within 134 days. Previously, Stephen Unger worked at NEEDHAM.
Stephen Unger’s has documented 126 price targets and ratings displayed on 13 stocks. The coverage was on Healthcare, Technology, Industrials sectors.
Most recent stock forecast was given on NEO, NeoGenomics at 29-Mar-2022.
Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for OCX (ONCOCYTE CORP) at 11/13/2020. The price target of $4 was fulfilled within 68 days with a profit of $2.26 (129.89%) receiving and performance score of 19.1.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$57
$6.18 (12.16%)
$77
8 days ago
(14-Feb-2025)
7/8 (87.5%)
$5.85 (11.44%)
145
Buy
$60
$9.18 (18.06%)
$65
8 days ago
(14-Feb-2025)
0/3 (0%)
$8.85 (17.30%)
Buy
$80
$29.18 (57.42%)
$90
2 months 9 days ago
(13-Dec-2024)
0/2 (0%)
$22.27 (38.58%)
Hold
$66
$15.18 (29.87%)
$90
2 months 12 days ago
(10-Dec-2024)
13/14 (92.86%)
$6.02 (10.04%)
243
Hold
$60
$9.18 (18.06%)
$60
2 months 17 days ago
(05-Dec-2024)
7/7 (100%)
$1.52 (2.60%)
135
What Year was the first public recommendation made by Stephen Unger?
